Article

Structure and function of mammalian facilitative sugar transporters.

Howard Hughes Medical Institute, University of Chicago, Illinois 60637.
Journal of Biological Chemistry (Impact Factor: 4.6). 10/1993; 268(26):19161-4.
Source: PubMed
0 Bookmarks
 · 
55 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this work we evaluated several genes involved in gluconeogenesis, glycolysis and glycogen metabolism, the major pathways for carbohydrate catabolism and anabolism, in the BME26 Rhipicephalus microplus embryonic cell line. Genetic and catalytic control of the genes and enzymes associated with these pathways are modulated by alterations in energy resource availability (primarily glucose). BME26 cells in media were investigated using three different glucose concentrations, and changes in the transcription levels of target genes in response to carbohydrate utilization were assessed. The results indicate that several genes, such as glycogen synthase (GS), glycogen synthase kinase 3 (GSK3), phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6 phosphatase (GP) displayed mutual regulation in response to glucose treatment. Surprisingly, the transcription of gluconeogenic enzymes was found to increase alongside that of glycolytic enzymes, especially pyruvate kinase, with high glucose treatment. In addition, RNAi data from this study revealed that the transcription of gluconeogenic genes in BME26 cells is controlled by GSK-3. Collectively, these results improve our understanding of how glucose metabolism is regulated at the genetic level in tick cells.
    International Journal of Molecular Sciences 01/2014; 16(1):1821-39. DOI:10.3390/ijms16011821 · 2.46 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Current tools for monitoring response to tuberculosis treatments have several limitations. Noninvasive biomarkers could accelerate tuberculosis drug development and clinical studies, but to date little progress has been made in developing new imaging technologies for this application. In this study, we developed pulmonary iodo-DPA-713 single-photon emission computed tomography (SPECT) to serially monitor the activity of tuberculosis treatments in live mice, which develop necrotic granulomas and cavitary lesions. C3HeB/FeJ mice were aerosol infected with Mycobacterium tuberculosis and administered either a standard or a highly active bedaquiline containing drug regimen. Serial [(125)I]DPA-713 SPECT imaging was compared with [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) and standard microbiology. Ex vivo studies were performed to characterize and correlate DPA-713 imaging with cellular and cytokine responses. Pulmonary [(125)I]DPA-713 SPECT, but not [(18)F]FDG PET, was able to correctly identify the bactericidal activities of the two tuberculosis treatments as early as four weeks after starting treatment (P < 0.03). DPA-713 readily penetrated the fibrotic rims of necrotic and cavitary lesions. A time dependent decrease in both TNF-α and IFN-γ levels was observed with treatments, with [(125)I]DPA-713 SPECT correlating best with tissue TNF-α levels (ρ = 0.94; P < 0.01). [(124)I]DPA-713 was also evaluated as a PET probe and demonstrated a 4.0-fold higher signal intensity in the infected tuberculous lesions compared to uninfected controls (P = 0.03). These studies provide proof-of-concept for application of a novel noninvasive imaging biomarker to monitor tuberculosis treatments, with potential for translation to humans. Copyright © 2014, American Society for Microbiology. All Rights Reserved.
    Antimicrobial Agents and Chemotherapy 11/2014; 59(1). DOI:10.1128/AAC.04180-14 · 4.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multi-modal imaging approaches of tumor metabolism that provide improved specificity, physiological relevance and spatial resolution would improve diagnosing of tumors and evaluation of tumor progression. Currently, the molecular probe FDG, glucose fluorinated with (18)F at the 2-carbon, is the primary metabolic approach for clinical diagnostics with PET imaging. However, PET lacks the resolution necessary to yield intratumoral distributions of deoxyglucose, on the cellular level. Multi-modal imaging could elucidate this problem, but requires the development of new glucose analogs that are better suited for other imaging modalities. Several such analogs have been created and are reviewed here. Also reviewed are several multi-modal imaging studies that have been performed that attempt to shed light on the cellular distribution of glucose analogs within tumors. Some of these studies are performed in vitro, while others are performed in vivo, in an animal model. The results from these studies introduce a visualization gap between the in vitro and in vivo studies that, if solved, could enable the early detection of tumors, the high resolution monitoring of tumors during treatment, and the greater accuracy in assessment of different imaging agents.
    American Journal of Nuclear Medicine and Molecular Imaging 01/2015; 5(1):1-13. · 3.25 Impact Factor